Plasma lyso-Gb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes

被引：1

作者：

Nowak, Albina ^{[1
]}

Mechtler, Thomas P. ^{[2
]}

Desnick, Robert J. ^{[3
]}

Kasper, David C. ^{[4
]}

机构：

[1] Univ Zurich Hosp, Zurich, Switzerland

[2] Univ Hosp Zurich, Vienna, Austria

[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[4] ARCHIMED Life Sci, Vienna, Austria

来源：

MOLECULAR GENETICS AND METABOLISM | 2017年 / 120卷 / 1-2期

关键词：

Biomarker; Fabry disease; Heterozygotes; LysoGb3; α-galactosidase deficiency;

D O I：

10.1016/j.ymgme.2016.11.262

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

253

引用

页码：S103 / S104

页数：2

共 50 条

[31] Fabry Disease: Treatment and Diagnosis
Rozenfeld, Paula A.
IUBMB LIFE, 2009, 61 (11) : 1043 - 1050
[32] Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
Revel-Vilk, Shoshana
Fuller, Maria
Zimran, Ari
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 33
[33] Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease
Hurvitz, Noa
Dinur, Tama
Becker-Cohen, Michal
Cozma, Claudia
Hovakimyan, Marina
Oppermann, Sebastian
Demuth, Laura
Rolfs, Arndt
Abramov, Aya
Zimran, Ari
Revel-Vilk, Shoshana
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (12):
[34] Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey
Zimran, Ari
Revel-Vilk, Shoshana
Dinur, Tama
Istaiti, Majdolen
Botha, Jaco
Lukina, Elena
Giraldo, Pilar
Deegan, Patrick
vom Dahl, Stephan
ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
[35] Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy
Frustaci, Andrea
Verardo, Romina
Magnocavallo, Michele
Scialla, Rossella
Sansone, Luigi
Russo, Matteo Antonio
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (12)
[36] Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
Liu, Hao-Chuan
Lin, Hsiang-Yu
Yang, Chia-Feng
Liao, Hsuan-Chieh
Hsu, Ting-Rong
Lo, Chiao-Wei
Chang, Fu-Pang
Huang, Chun-Kai
Lu, Yung-Hsiu
Lin, Shuan-Pei
Yu, Wen-Chung
Niu, Dau-Ming
ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
[37] Fabry disease. Diagnosis and treatment
Ueceyler, N.
Sommer, C.
SCHMERZ, 2012, 26 (05): : 609 - 618
[38] Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
Hao-Chuan Liu
Hsiang-Yu Lin
Chia-Feng Yang
Hsuan-Chieh Liao
Ting-Rong Hsu
Chiao-Wei Lo
Fu-Pang Chang
Chun-Kai Huang
Yung-Hsiu Lu
Shuan-Pei Lin
Wen-Chung Yu
Dau-Ming Niu
Orphanet Journal of Rare Diseases, 9
[39] Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease
Togawa, Tadayasu
Kawashima, Ikuo
Kodama, Takashi
Tsukimura, Takahiro
Suzuki, Toshihiro
Fukushige, Tomoko
Kanekura, Takuro
Sakuraba, Hitoshi
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 399 (04) : 716 - 720
[40] Guidelines for diagnosis, monitoring and treatment of Fabry disease
Neumann, Pablo
Antongiovanni, Norberto
Fainboim, Alejandro
Kisinovsky, Isaac
Amartino, Hernan
Cabrera, Gustavo
Carmona, Sergio
Ceci, Romina
Ciceran, Alberto
Choua, Martin
Doxastakis, Griselda
De Maio, Sonia
Ebner, Roberto
Maria Escobar, Ana
Ferrari, Gustavo
Forrester, Mariano
Guelbert, Norberto
Luna, Paula
Marchesoni, Cinthia
Masllorens, Francisca
Politei, Juan
Reisin, Ricardo
Ripeau, Diego
Rozenfeld, Paula
Serebrinsky, Graciela
Lia Tarabuso, Ana
Tripoli, Juan
MEDICINA-BUENOS AIRES, 2013, 73 (05) : 482 - 494

← 1 2 3 4 5 →